CFHR3 is a potential novel biomarker for hepatocellular carcinoma

@article{Liu2019CFHR3IA,
  title={CFHR3 is a potential novel biomarker for hepatocellular carcinoma},
  author={Jun Liu and Wenli Li and Hetong Zhao},
  journal={Journal of Cellular Biochemistry},
  year={2019},
  volume={121},
  pages={2970 - 2980}
}
Complement factor H‐related 3 (CFHR3) is a protein‐coding gene acting in various diseases. However, its prognostic values of CFHR3 in hepatocellular carcinoma (HCC) are not understandable. Therefore, we present a further study on CFHR3 in HCC. CFHR3 expression data were acquired from The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC). We compared the differential expression of CFHR3 between the low‐stage (stage I and II) and high‐stage (stage III and IV… 
View on Wiley
ncbi.nlm.nih.gov
16 Citations
Highly Influential Citations
4
Background Citations
5
Methods Citations
2
Results Citations
2

16 Citations

Low Complement Factor H-Related 3 (CFHR3) Expression Indicates Poor Prognosis and Immune Regulation in Cholangiocarcinoma

An elevated expression level of CFHR3 in normal tissues as well as a lower expression level in cholangiocarcinoma tissues in the present research revealed an elevated correlation between this signature and complement and coagulation cascades.

GDI2 is a novel diagnostic and prognostic biomarker in hepatocellular carcinoma

The elevated expression of GDI2 predicts poor prognosis in HCC patients, indicating that GDI 2 could be applied as a predictive biomarker for diagnosis and prognosis of HCC.

Risk model of hepatocellular carcinoma based on cuproptosis-related genes

A cuproptosis-related prognostic risk model comprising seven genes was established in this study, which could assist in predicting the prognosis and identifying the patients benefit from immunotherapy.

Analysis on heterogeneity of hepatocellular carcinoma immune cells and a molecular risk model by integration of scRNA-seq and bulk RNA-seq

An eight-gene prognostic stratification signature was developed based on the heterogeneity of HCC immune cells to precisely assess the prognostic risk, and revealed that autophagy-related pathways were more enriched in malignant tumors.

Prediction of hepatocellular carcinoma prognosis and immunotherapeutic effects based on tryptophan metabolism-related genes

A risk model that could be used for predicting prognosis and guiding immunotherapy in patients with hepatocellular carcinoma is established and two metabolic phenotypes based on genes of the Trp metabolism pathway are identified.

Transcriptomic Analysis and Novel Gene Pair-Based Signatures for Hepatitis B-Related Hepatocellular Carcinoma.

A powerful diagnostic signature of two pairs of DEGs was built and validated in TCGA-LIHC and GEO datasets repeatedly with assured performance and a novel strategy for the early diagnosis and prognosis for HBV-related HCC is provided.

Decreased DHRS1 expression is a novel predictor of poor survival in patients with hepatocellular carcinoma.

Investigation of the effect of aberrant expression of DHRS1 on hepatocellular carcinoma revealed thatDHRS1 mRNA and protein expression level were remarkably lower in HCC than that in normal tissues.

Exploration of Potential Biomarkers and Immune Landscape for Hepatoblastoma: Evidence from Machine Learning Algorithm

The results of single-sample gene-set enrichment analysis (ssGSEA) and deconvolution methods revealed a more active immune responses in the HB tissue and developed a robust biomarkers panel for HB patients.

“Complimenting the Complement”: Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma

Derangement of specific complement proteins in HCC is reviewed in the context of altered complement regulatory factors, immune-activating components, and their implications in disease pathogenesis.

Identification of Ten Core Hub Genes as Potential Biomarkers and Treatment Target for Hepatoblastoma

A random forest classifier was established that identified 10 core genes in HB that may be beneficial for the diagnosis, prediction, and targeted therapy of HB.

40 References

The AP2M1 gene expression is a promising biomarker for predicting survival of patients with hepatocellular carcinoma

The AP2M1 level showed excellent prognosis predictions in comparison with existing markers in the three independent cohorts and was more predictive of prognosis than other markers in alcohol intake and HCV infections.

ADAMTSL4, a Secreted Glycoprotein, Is a Novel Immune-Related Biomarker for Primary Glioblastoma Multiforme

Investigation of the role of ADAMTSL4 at transcriptome level and its relationship with clinical practice in glioblastoma multiforme found that it was enriched in GBM (WHO grade IV), especially for those with IDH1/2 wild-type and MGMT unmethylated groups.

Identification of the potential therapeutic target gene UBE2C in human hepatocellular carcinoma: An investigation based on GEO and TCGA databases

The results of the present study suggest that the overexpression of UBE2C may be used as a novel prognostic biomarker of HCC.

Deletion Variants of CFHR1 and CFHR3 Associate with Mesangial Immune Deposits but Not with Progression of IgA Nephropathy.

The CFHR3,1Δ genotype did not associate with progression toward CKD stages 3 and 5 in the white population of patients with IgAN, although it did associate with a reduced level of glomerular immune deposits.

Complement proteins C7 and CFH control the stemness of liver cancer cells via LSF-1.

Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates in Hepatocellular Carcinoma

Inhibition of PD-L1+ ICs and TGF-β activity and their respective immunomodulatory pathways may contribute to antitumor effects in HCC.

High Complement Factor H-Related (FHR)-3 Levels Are Associated With the Atypical Hemolytic-Uremic Syndrome-Risk Allele CFHR3*B

It is revealed that the aHUS-risk haplotype CFH(H3)–CFHR3*B– CFHR1*B generates twofold more FHR-3 than the non-risk CFH (H1)– CF HR3*A–CF HR1*A haplotype and CFHR3-3 levels were higher in patients with aH US than in control individuals with the same CFHR2 genotype.

HCCDB: A Database of Hepatocellular Carcinoma Expression Atlas

Retinoblastoma protein potentiates the innate immune response in hepatocytes: Significance for hepatocellular carcinoma

It is found that RB depletion in hepatoma cells resulted in a compromised immunological response to multiple stimuli and reduced the potential of these cells to recruit myeloid cells, which confirmed that RB participates in the regulation of innate immunity in liver parenchymal cells both in vitro and in vivo.

A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy.